J&J Q2 results
This article was originally published in The Gray Sheet
Ethicon sales rose 8.2% to $1.13 billion in the second quarter, driven by sutures, biosurgicals and Mentor aesthetic devices, Johnson & Johnson reported July 20. The acquisition of Acclarent also contributed to growth, the firm noted. J&J bought the Balloon Sinuplasty developer for $785 million in December (1"The Gray Sheet" Dec. 21, 2009). Advanced sterilization and Harmonic ultrasonic devices helped grow Ethicon Endo-Surgery revenues 6.6% to $1.2 billion. The Cordis division continued to struggle, with sales dropping 2.8% to $655 million. Medical devices and diagnostics sales of $6.1 billion were up 3.5% overall
You may also be interested in...
Johnson & Johnson/Ethicon will use its $785 million acquisition of Acclarent, developer of the Balloon Sinuplasty system for chronic sinusitis, as a platform for growth in the ear, nose and throat business
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.